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ABSTRACT
The Sleeping Beauty (SB), piggyBac (PB) and Tol2
transposons are promising instruments for genome
engineering. Integration site profiling of SB, PB and
Tol2 in human cells showed that PB and Tol2 inser-
tions were enriched in genes, whereas SB insertions
were randomly distributed. We aimed to introduce
a bias into the target site selection properties
of the transposon systems by taking advantage
of the locus-specific integration system of adeno-
associated virus (AAV). The AAV Rep protein binds
to Rep recognition sequences (RRSs) in the human
genome, and mediates viral integration into nearby
sites. A series of fusion constructs consisting of
the N-terminal DNA-binding domain of Rep and the
transposases or the N57 domain of SB were
generated. A plasmid-based transposition assay
showed that Rep/SB yielded a 15-fold enrichment
of transposition at a particular site near a targeted
RRS. Genome-wide insertion site analysis indicated
that an approach based on interactions between the
SB transposase and Rep/N57 enriched transgene
insertions at RRSs. We also provide evidence of
biased insertion of the PB and Tol2 transposons.
This study provides a comparative insight into
target site selection properties of transposons, as
well as proof-of-principle for targeted chromosomal
transposition by composite protein–protein and
protein–DNA interactions.
INTRODUCTION
The prospect to manipulate the genome of somatic cells of
a patient in order to correct a genetic deficiency holds
promise for the treatment of numerous inherited and
acquired diseases. One major hurdle to overcome is the
development of gene therapy vectors that ensure efficient
delivery and sustained expression of therapeutic trans-
genes while minimizing potential side-effects. Retroviral
and lentiviral vectors can efficiently deliver transgenes
into cells, and have the potential to provide long-term
transgene expression by stably integrating into the target
cell’s genome (1). However, large-scale surveys on the in-
tegration site distribution of HIV-1 revealed a preference
for integrations to occur in actively transcribed genes (2).
Similar studies showed that the murine leukaemia virus
(MLV) has a strong preference for integrating into
regions surrounding transcription start sites (3). Thus,
the bias in the integration profiles of retroviral gene
therapy vectors may result in insertional mutagenesis (4)
by activating oncogenes, as observed in clinical trials for
SCID-X1 (5,6), X-CGD (7) and WAS (8).
Another promising vector system for gene therapy is
based on the adeno-associated virus (AAV). In the
absence of a helper virus AAV establishes latency by
preferentially integrating its genome locus-specifically
into a region on the q arm of human chromosome 19
(19q13.3-qter) termed AAVS1 (9). The only factors
needed for targeted integration are the viral cis-acting
inverted terminal repeats (ITRs), and the trans-acting
viral Rep proteins (Rep). The ITRs have a binding site
for the Rep proteins, an imperfect tetrameric GAGC
tandem repeat termed Rep-recognition sequence (RRS)
(10). Locus-specific integration of the viral genome is
determined by DNA sequences present in the AAVS1
locus. A 33-bp sequence encompassing the RRS motif
was shown to be necessary and sufficient to mediate
targeted integration (11). The viral Rep proteins bind sim-
ultaneously to the RRSs in the viral ITRs and in the
genomic AAVS1 locus, introduce a nick at the genomic
site and integrate the AAV genome through non-
homologous recombination (involving partial duplication
of the target locus) (Figure 1A) (12). AAV provides
several advantages as a gene delivery vehicle. The virus
shows no pathogenicity, and is able to efficiently transduce
various proliferating and non-proliferating cells (13–17).
Serious limitations of AAV for gene therapy are the
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negative effects of the large Rep proteins on cell viability
as they were shown to induce DNA damage, cell-cycle
arrest and apoptosis (18). This led to the development of
recombinant AAV vectors (rAAV) (19) that lack the Rep
genes and therefore persist primarily as episomes in the
cell. Nevertheless, rAAV vectors can genomically integrate
with a preference for integration into transcription start
sites and CpG islands (20). Plasmid-based systems using
one plasmid harbouring a gene of interest flanked by AAV
ITRs and another expressing the Rep protein have been
used to support AAVS1-specific integration (21,22). Other
approaches utilized AAV hybrid viruses conditionally ex-
pressing the Rep protein (23). AAV-based vectors are
involved in diverse gene therapy approaches such as
clinical trials for the treatment of hemophilia B (24),
rheumatoid arthritis (25) or Parkinson’s disease (26)
with modest success and serious complications due to a
cytotoxic T lymphocyte response to the AAV capsid (27).
DNA transposons are powerful alternatives to viral
vectors as well as classical non-viral delivery systems.
Transposons are discrete DNA sequences with the
ability to move from one genomic location to another
via a cut-and-paste mechanism, in which the transposon
gets excised from the donor locus and is subsequently re-
inserted elsewhere in the genome. This transpositional
mechanism can be adapted to the crafting of gene
delivery vectors, in which transposition out of engineered,
plasmid-based vectors forms the basis of stable genomic
insertion of gene constructs. Transposon-based vector
systems typically consist of two components, the trans-
poson and the transposase. The inverted repeats (IRs) of
the transposon that flank a gene of interest to be mobilized
contain transposase-binding sites. Transposases typically
have two major functional domains: an N-terminal part
mediating binding to the transposon IRs, protein
multimerization and nuclear transport and a C-terminal
Figure 1. Experimental strategies for targeting transposition. (A) Site-directed integration of the AAV. The viral Rep proteins (blue ovals) bind to a
RRS in the viral ITRs and in the human genome, and mediate site-specific integration of the viral genome adjacent to genomic RRS sites. (B–D)
Strategies for transposon targeting. The transposable element is composed of the IRs (blue arrows) flanking a gene of interest (grey box) equipped
with a suitable promoter (black arrow). The transposase (Tpase, spheres) binds to the IRs and catalyses transposition. The DNA-binding domain of
Rep (blue oval) recognizes an RRS (green box) in the target DNA (parallel lines). (B) Targeting with transposase fusion proteins. Targeting is
achieved by fusing the DNA-binding domain of Rep to the transposase. (C) Targeting with proteins that bind the transposon DNA. Targeting
is achieved by the DNA-binding domain of Rep that simultaneously interacts with RRS sites present in the transposon and in the target DNA.
(D) Targeting with fusion proteins that interact with the transposase. Targeting is achieved by fusing the DNA-binding domain of Rep to the N57
domain (beige oval) that interacts with the SB transposase. Figure redrawn from (71).
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catalytic domain responsible for the DNA cleavage and
integration reactions required for transposition (28).
Virtually any gene of interest can be cloned between the
IRs and mobilized by supplying the transposase function.
Hence, transposon-based gene therapy vectors offer
robust, stable delivery of the desired gene and thus
long-term expression. Clinical-grade, plasmid-based trans-
poson vectors can be prepared from well-defined compo-
nents at much reduced costs and with presumably lower
immunogenicity than viral vectors. The three most widely
used DNA transposons in vertebrates are the Sleeping
Beauty (SB), piggyBac (PB) and Tol2 transposon
systems. The SB transposon was resurrected from
multiple inactive Tc1/mariner elements found in fish
genomes (29). SB transposition exclusively occurs into
TA dinucleotides, which are duplicated upon transposon
insertion by cellular DNA repair pathways (30). Extensive
efforts were made to enhance the transposition efficiency
of SB, yielding a set of hyperactive transposase versions
with SB100X being the most active transposase to date
(31). The SB transposon system has been used to correct
several genetic deficiencies in pre-clinical animal models
including those for tyrosinemia type I (32), Huntington
disease (33), hemophilia A and B (34–38), junctional epi-
dermolysis bullosa (39), mucopolysaccharidosis (40,41),
type 1 diabetes (42) and glioblastoma (43,44). In 2008
the National Institute of Health Recombinant DNA
Advisory Committee (NIH RAC) approved the
first-in-man gene therapy clinical trial that uses trans-
posons. This trial is using the SB transposon/transposase
system to generate genetically modified autologous T cells
that are transferred into patients with CD19+B-lymphoid
malignancies (45). The PB transposon was first identified
in the cabbage looper moth Trichoplusia ni as an active
transposon moving from the host genome into a baculo-
virus genome (46). PB integrates exclusively at TTAA
tetranucleotide sequences that are duplicated upon inser-
tion (47). PB elements have been extensively used for
germline transgenesis in a wide range of insect species
(48), and were also found to efficiently transpose in
human and mouse cell lines and in mice in vivo (49). The
Tol2 transposon was first identified in the genome of the
medaka fish Oryzias latipes, and is the only known natur-
ally occurring active DNA transposon of vertebrate origin
(50). Tol2 transposons show no obvious requirements for
primary DNA sequence for insertion, and create 8-bp
target-site duplications (51). Tol2 is the preferred trans-
poson system for transgenesis and insertional mutagenesis
in zebrafish, but also efficiently transposes in cultured
mammalian cell lines (52). On the genomic scale, SB trans-
posons exhibit a random integration profile with a target
site selection primarily determined by physical properties
of the DNA rather than primary DNA sequences
(30,53–56). In contrast, PB transposons have a
non-random genomic integration profile with a preference
for integrating into genes and regions surrounding tran-
scriptional start sites (49,53), whereas Tol2 shows prefer-
ences for integrating into transcription units and close to
transcription start sites (53). Thus, in addition to its
potency in catalysing robust gene transfer in primary cell
types, including stem cells (53), a key feature of turning SB
to an attractive gene therapy tool is its fairly random in-
tegration profile, which might make it safer than
integrating viral vectors. Even though SB exhibits a
fairly random integration profile, arbitrary integration of
a transposon can still be potentially mutagenic, because
an internal promoter/enhancer present in the transgene
construct could negatively influence the regulation of en-
dogenous genes. Random genomic integration may also
limit transgene expression through silencing by position
effects. One possibility to alleviate the danger of random
transposon integration is targeting of the transposon
complex to a specific chromosomal region, where insertion
is not predicted to have mutagenic effects.
Attempts to achieve targeted transposition by using
hybrid DNA-binding domain-transposase enzymes were
undertaken by several research groups. Most of these
efforts showed biased transposon insertion into plasmid
targets, but no targeted transposition has ever been shown
on the genome level. For example, fusions of the bacterial
IS30 transposase with the  repressor and with the
DNA-binding domain of the transcription factor Gli1
showed altered insertion profiles in plasmid targets in
Escherichia coli and zebrafish embryos (57). A chimeric
transposase protein composed of a zinc-finger (ZF)
DNA-binding domain from the mouse transcription
factor Zif268 fused to the C-terminus of the
Synechochystis transposon ISY100 was efficiently target-
ing transposition into a region adjacent to a Zif268-
binding site on a target plasmid (58). Finally, fusions of
the polydactyl ZF protein E2C and the SB transposase
retained DNA-binding specificity for the E2C-binding
site, were capable of mediating bona fide transposition
reaction and could direct SB transposition into the
vicinity of an E2C-binding site in plasmids, but not in
the genome (59).
We performed a large-scale, genome-wide, comparative
analysis of target site selection properties of SB, PB and
Tol2 transposons, and evaluated the potential of
transposase fusion proteins to target transposition in the
human genome. We aimed to mimic the site-specific inte-
gration ability of AAV and to target transposon integra-
tions near genomic Rep-binding sites. We considered three
molecular strategies, all based on the specific RRS
DNA-binding activity of the AAV Rep proteins. Based
on the binary nature of the transposon vector systems,
tethering of the transpositional complex could be
achieved by interactions with either the transposase
enzyme or the transposon DNA. The first targeting
strategy involves a fusion of the site-specific DNA-
binding domain of Rep to the transposase polypeptide
(Figure 1B). In this setup the transposase fusion protein
is predicted to bind site-selectively to a Rep-binding
sequence in the genome, thereby tethering the transpos-
ition complex to this region and to mediate transposon
integration into nearby sites. The second, more indirect,
approach was to use the Rep DNA-binding domain that
simultaneously binds RRS sites engineered into the trans-
poson vectors and RRS target sites in the human genome,
thereby mimicking the locus-specific insertion of AAV
(Figure 1C). The third strategy (only applicable to the
SB system) relied on non-covalent binding activities of a
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third protein. This protein combines site-selective
DNA-binding functions with the ability to form protein–
protein interactions with the SB transposase. The protein
acts as a bridge or adapter that is designed to target the
transpositional complex to endogenous RRS motifs in the
genome through protein–protein interactions with the SB
transposase polypeptide (Figure 1D). A series of hybrid
proteins consisting of Rep and the SB, PB or Tol2
transposases were engineered, and their activities in the re-
spective transposition reactions were confirmed. We also
tested the DNA-binding activities of the Rep/transposase
fusions and performed a plasmid-based transposition
assay to assess site-directed transposon integration.
Finally, we used Illumina sequencing and chromosomal
mapping of transposon insertion sites to determine
overall target site distribution of the three transposon
systems as well as enrichment of insertions close to
genomic RRS sequences. We provide proof-of-principle
that fusion protein-mediated tethering can effectively
redirect transposon insertion site selection in human cells.
MATERIALS AND METHODS
Plasmid constructs
The AAV Rep DNA-binding domain originated from a
pcDNA3.1/Myc-His (Invitrogen, CarlSBad, CA) expres-
sion plasmid containing the amino-terminal 244 residues
of the AAV Rep78 protein (pcDNARepTZ) (60). The SB
expression plasmids were produced by PCR amplification
of the AAV Rep DNA-binding domain and, if appropri-
ate, together with a GCN4-based wild-type leucine zipper
domain (LZ) or an engineered GCN4-based leucine zipper
oligomerization domain (TZ). The Rep DNA-binding
domain was then ligated in frame to the N-terminus of
the hyperactive SB transposase M3a present in a
pEGFP-C1 (Clontech) expression vector. The RepTZ/
N57 expression plasmid was made by PCR amplification
of the 56 amino-acids (excluding the initiator methionine)
N-terminal helix–turn–helix domain of the SB transposase
and subsequently insertion into the pcDNARepTZ vector
creating pcDNARepTZ/N57. The Rep/N57 expression
plasmid was constructed by replacing the RepTZ
fragment with a Rep fragment in pcDNARepTZ/N57.
The effector plasmids were generated by inserting Rep/
N57 and RepTZ/N57 into a herpes simplex virus VP16
transcriptional activation domain (AD) containing expres-
sion plasmid, yielding Rep/N57-AD and RepTZ/
N57-AD. The HA–ADRep/N57 and HA–ADRepTZ/
N57 expression plasmids were generated by inserting
Rep/N57 and RepTZ/N57 into a pRK5–AD expression
vector. The PB fusion proteins were produced by PCR
amplification of the PB coding sequence from a PB
ORF helper plasmid and subsequent insertion into the
Rep expression vector. RepTZL/PB was generated by
introducing a double-stranded oligonucleotide coding for
a flexible linker (KLGGGAPAVGGGPK) in between the
RepTZ and the PB transposase sequence of RepTZ/PB.
The Tol2 fusion vector was generated by PCR amplifica-
tion of the Tol2 transposase coding sequence and subse-
quent insertion into the pcDNARepTZ expression
plasmid. With the incorporation of the double-stranded
oligonucleotide flexible linker (KLGGGAPAVGGGPK)
in between Rep and the Tol2 transposase the RepL/Tol2
expression plasmid was generated. The SB transposon
donor plasmid pTneoRRS was generated by inserting a
double-stranded oligonucleotide containing a single repeat
of the RRS into the pTneo plasmid (29). In order to
generate the pXLSV40neoRRS PB donor plasmid a set
of two anti-parallel oligonucleotides containing a single
copy of the RRS motif were inserted into a neomycin
containing PB transposon vector (53). The pTol2neo
RRS donor vector was generated by inserting a
double-stranded RRS fragment into the pTol2neo trans-
poson vector (53).
Transposition and western blot analysis
The transposition assay was used to assess the integration
capabilities of the fusion transposases. A total of 5 105
HeLa cells were transfected with 500 ng of a neomycin
containing transposon donor plasmid and 50 ng of a
fusion transposase, unmodified transposase or green fluor-
escent protein (GFP) expression plasmid using the
JetPEITM transfection reagent (Polyplus transfection) ac-
cording to the manufacturer’s instructions. Two days
post-transfection cells were seeded on 10-cm diameter
dishes, and selected in DMEM supplemented with
600 mg/ml G418 (Biochrom). Fourteen days later selection
was terminated by fixing and staining the neomycin resist-
ant colonies. To determine the relative transposition effi-
ciency, the number of G418-resistant colonies on each
plate were counted and compared to the number of
G418-resistant colonies obtained with the wild-type
transposase. The expression of the fusion proteins was
tested by western blot analysis. HeLa cells were trans-
fected with 1 mg of fusion transposases expression
plasmids or GFP expression plasmid as a control. Two
days later cells were lysed in protein lysis buffer supple-
mented with protease inhibitor mixture (Roche) and
proteins were extracted. Equal concentrations of
proteins were separated on a 10% polyacrylamide gel,
transferred onto nitrocellulose membranes and incubated
with goat polyclonal anti-SB transposase antibody (R&D
Systems) or an anti-HA high-affinity antibody (Roche).
The bound antibodies were visualized by chemilumines-
cence (ECL Plus western blotting detection system) and
signals were captured on a film.
PCR-based excision assay
The PCR-based excision assay was performed in order
to monitor the transposon excision activity of the
transposase chimeras in human cells. HeLa cells were
transfected with 500 ng of a neomycin resistance
gene-containing transposon donor plasmid and 50 ng of
a fusion transposase, a wild-type transposase or an expres-
sion plasmid for the GFP. Two days post-transfection
cells were harvested, low molecular weight DNA was
isolated and used as template for nested PCR reactions.
Primer pairs flanking the transposon donor sites enable
the amplification of transposon footprint products that
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are generated after transposon excision and repair of the
excision site.
Luciferase reporter assay
The RRS-binding capabilities of the transposase fusion
proteins were tested in a luciferase-reporter assay.
Triplicates of 5 105 HeLa cells were each transfected
with 50 ng of the pRRStkLuc reporter plasmid, 15 ng of
the pcDNARepTZ–AD activator plasmid, 935 ng of fused
or unfused transposase expression plasmid and 100 ng of
pCMV-bgal (Clonetech) as an internal control for the
transfection efficiency. Two days post-transfection, cells
were prepared and analysed on a luminometer following
the instructions of the Dual-Luciferase Reporter Assay
System protocol (Promega). The measured luciferase
activities were related to the total amount of protein in
the lysates.
Co-immunoprecipitation
Cultured HeLa cells were plated into 10-cm diameter
dishes and transfected with 3 mg of plasmids encoding
HA-tagged, untagged or Myc-tagged protein. Forty-
eight post-transfection cells were lysed in 1ml of protein
lysis buffer supplemented with protease inhibitor mixture
(Roche) and incubated on a shaker at 4C for 15min.
All of the procedures were done at 4C. The lysates were
pre-clarified with 20 ml of protein G-agarose (Sigma) and
subsequently incubated with 40 ml of EZviewTM Red
Anti-HA Affinity Gel (Sigma). The captured immuno-
complexes were treated according to the manufacturers
instruction and analysed by immunoblotting using either
a polyclonal goat anti-SB transposase antibody (R&D
systems), a monoclonal rat anti-HA high affinity
antibody (Roche) or a polyclonal rabbit anti-Myc
antibody (Abcam).
Inter-plasmid transposition assay
The targeting potential of the fusion proteins was
determined by analysing the integration site distribution
of a kanamycin-marked transposon into pre-defined target
DNA molecules. We transfected 5 105 HeLa cells with
200 ng of a kanamycin donor plasmid, 500 ng of either
pFVLuc or pFVLuc5xRRS target plasmid and 320 ng of
fusion transposase expression plasmid. For the
inter-plasmid transposition assay performed with the
N57 targeting protein the cells were transfected with
100 ng of the kanamycin-marked donor plasmid, 250 ng
of pFVLuc or pFVLuc5xRRS target plasmid, 20 ng of
SB helper plasmid and 500 ng of either Rep/N57 or
RepTZ/N57 fusion protein expression plasmid. Two
days post-transfection the cells were lysed and the low
molecular weight DNA was extracted using the Hirt
method. The plasmid DNA was electroporated into
ElectroMAX DH10B competent E. coli cells (Invitrogen)
according to the manufacturer’s instructions. The trans-
formation mix was plated on an LB agar plate containing
100 mg/ml ampicillin and 25 mg/ml kanamycin. Plasmid
DNA samples isolated from colonies growing on amp/
kan plates were pre-screened by diagnostic restriction
digests, and further analysed by DNA sequencing using
transposon-specific primers.
Construction of integration site libraries
In order to assess the chromosomal targeting capabilities
of the fusion transposases integration site libraries were
generated by transfecting 1.5 105 HeLa with 90 ng
neomycin resistance gene-containing transposon plasmid
together with 9 ng of fusion or unfused transposase ex-
pression plasmid. In transfection experiments with one
of the targeting constructs that do not have transposase
capabilities, HeLa cell were transfected with 90 ng of
transposon plasmid, 9 ng of a transposase expression
plasmid and 450 ng of a targeting fusion protein expres-
sion plasmid. Two days post-transfection cells were
divided to several 10-cm diameter dishes and set on
G418 selection over a period of 2weeks. At this point,
approximately 10 000 G418-resistant colonies were
pooled together and used to isolate genomic DNA. The
isolated DNA samples were randomly fragmented by son-
ication and sequences neighboring the insertion sites were
amplified by a modified linear amplification-mediated
PCR (LAM–PCR) (55,61). Briefly, vector-genome junc-
tions were pre-amplified in a linear PCR with primer
specific for the transposon IRs, the PCR products were
double-stranded and ligated to linkers with known se-
quences. The DNA fragments consisting of a linker
cassette-, genomic- and transposon-sequences were then
subjected to nested PCRs that amplify the vector
genome junctions with primer that anneal to the trans-
poson IRs and to the linker. During the amplification
we used barcoded primer that allowed us to pool the
libraries. Finally, the samples were prepared for
high-throughput sequencing by an additional PCR
adding the Illumina-specific adaptor sequences required
for the solid-phase bridge amplification. The PCR
products were purified, pooled and then subjected to
high throughput sequencing on the Illumina/Solexa
Genome Analyser IIx platform with single end run
settings. Primer and linker sequences are specified in
Supplementary Methods.
Computational analysis
We used a set of error-correcting barcodes for distinguish-
ing different data sets pooled into a single Illumina
Genome Analyser IIx flow cell lane. The 76-bp long
sequencing reads were checked for starting exactly with
the barcode (4 bp) followed by the adapter sequence (23
bp for SB, 24 bp for PB and 22-bp for Tol2). The adapter
for SB ended with ‘TA’ and the adapter for PB with
‘TTAA’ indicating transposase-mediated transposition
events as opposed to random integration. The remaining
parts of the reads (between 48 and 50 bp) were mapped
using Bowtie (62) to the chromosomes of the human
genome (NCBI built GRCh37/hg19, February 2009)
excluding the Y-chromosome because HeLa is a female
cell line. Only reads occurring without mismatches at a
single genomic position (exact uniquely mapped reads)
were used for the subsequent analysis. Multiple reads
mapping to the same genomic position and strand were
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treated as a single integration site. To improve the data
quality, we discarded all sites supported by <10 reads. In
case of the SB data sets, we only accepted sites having
‘TA’ adjacent to the integration site. In case of the PB
data sets, we only accepted sites having ‘TTAA’ adjacent
to the integration site. For the statistical analysis, we
generated three control sets, each containing 10 000 sites,
which were randomly selected from inside of contigs on
human chromosomes excluding the Y-chromosome. For
the SB control set, only control sites adjacent to ‘TA’ were
selected, and for the PB control set, only control sites
adjacent to ‘TTAA’ were selected. Databases of genomic
regions (RefSeq) were downloaded from UCSC (http://
genome.ucsc.edu). We used the H3K27me3 domains
determined by Cuddapah et al. (63) (GEO accession
number GSM325898). Regions enriched for H3K4me1
and H3K4me3 were determined as follows: The raw
ChIP-Seq reads by Robertson et al. (64) (http://www.
bcgsc.ca/data/histone-modification) were mapped to the
human genome using Bowtie, then peaks were called
using MACS (65), and H3K4me1/3 domains are then
defined as 5-kb windows around the centers of the
peaks. The search for RRS motifs was done by a custom
C++program.
RESULTS
Comparative analysis of target site selection of SB, PB
and Tol2 transposons in human cells
We generated integration site libraries for the SB, PB and
Tol2 transposons by transfecting cultured HeLa cells with
neo-marked transposon donor plasmids and transposase
expression plasmids. Approximately 10 000 antibiotic-
resistant colonies were pooled together and used to
extract genomic DNA. To recover genomic DNA
flanking the transposon integration sites, we performed a
modified LAM–PCR (55,61). In total we analysed 59 169
SB, 1397 PB and 2595 Tol2 genomic integration sites.
Integration sites were mapped onto the human genome,
and local features at the integration sites were quantified.
The three integration site data sets were analysed in
relation to various chromosomal features, and compared
to 10 000 computer-simulated random integrations. The
random control sites were matched to the experimental
sites with respect to the integration frequencies into
genes, exons, introns, regions around transcription start
sites (5-kb regions surrounding transcriptional start
sites; 5-kb±TSS), and sites of histone modifications.
We concentrated on analysing transposon integration
frequencies with regard to H3K4 mono-and trimethyla-
tion, a marker for active promoter (H3K4me3) and
enhancer regions (H3K4me1) associated with open chro-
matin (66), and trimethylated H3 K27 (H3K27me3), a
marker for condensed chromatin regions associated with
gene repression (67). The bioinformatic analysis revealed a
random integration profile for SB with no apparent bias
for integrating into genes or near transcriptional regula-
tory regions of genes (Figure 2). In contrast, PB showed a
non-random integration profile with significant bias
towards integrating into genes, transcription start sites
and their upstream regions (Figure 2). The Tol2 trans-
poson showed an intermediate integration profile with
no bias for inserting into genes, but preferential integra-
tion into transcription start sites and transcriptional regu-
latory regions (Figure 2). The biased integration of PB
and Tol2 transposons into transcriptional start sites
correlated with significant enrichment in chromatin
regions characterized by H3K4me3 and H3K4me1
associated with open chromatin (Figure 2). In sum, the
three transposon systems displayed different preferences
for local features of the target DNA, with SB being the
closest to showing a fully random integration profile in the
human genome.
Design and transpositional activities of Rep/SB fusion
proteins
The subsequent aim of the study was to introduce a meas-
urable bias into the target site selection properties of the
transposon systems by targeting transposon integrations
to predetermined chromosomal regions. We chose to in-
vestigate target-selected transposon insertion by mimick-
ing the site-specific integration mechanism of AAV. All
targeting strategies were based on the specific binding of
the AAV Rep proteins to a 16-bp imperfect GAGC re-
peating motif called RRS. The fusion transposases
comprised the 244 amino acid N-terminal DNA-binding
domain of the AAV Rep protein, sufficient for specific
binding to the RRS sequence (60), and hereafter
designated as Rep.
Figure 3A shows a sketch of the Rep/SB fusion protein
design. The monomeric form of the Rep protein does not
efficiently bind to DNA, whereas addition of oligomeriza-
tion motifs that induce the formation of multimers were
previously found to strongly enhance RRS-binding
activity (60). Fusion proteins containing the SB
transposase fused to Rep either directly or with a dimer-
ization domain of the yeast transcription factor GCN4
(LZ) or with a mutant GCN4 leucine zipper (TZ) pre-
dicted to assemble into a parallel tetramer (68) were en-
gineered. All fusion constructs were cloned under the
transcriptional control of the cytomegalovirus (CMV)
promoter and expression was confirmed by western blot
analysis (Figure 3B). The excision activities of the chimeric
transposases were tested in a plasmid-based excision
assay, during which the transposase excision activity is
assayed by polymerase chain reaction (PCR)-amplifica-
tion of the footprint that is left behind after transposon
excision from a donor plasmid (69). All three SB fusion
transposases showed detectable excision activity. Even
though the PCR assay is not designed to be quantitative,
it is useful for probing the overall potencies of
transposases in the excision reaction. Indeed, whereas
the Rep/SB transposase showed a transposon excision
activity close to that of the wild-type, unfused SB
transposase, RepLZ/SB and RepTZ/SB displayed only
weak excision activities (Figure 3C). The relative activities
of genomic integration catalysed by each fusion protein
were assessed by a standard colony-formation assay that is
based on acquisition of an antibiotic-resistant phenotype
as a result of stable genomic insertion of genetically tagged
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transposon constructs. In line with the excision data, the
Rep/SB fusion retained a high transpositional activity of
80% of the wild-type level, whereas the transpositional
activities of RepLZ/SB and RepTZ/SB were at only 20%
of the wild-type level (Figure 3D).
RRS-specific DNA-binding of the Rep/SB fusion proteins
The transposon excision and re-integration assays
demonstrated that the SB fusion proteins retained the
ability to catalyse authentic DNA transposition in
human cells, albeit at reduced frequencies. Thus, by def-
inition, the transposase hybrid proteins were still able to
bind the transposon end sequences despite the presence of
the large Rep DNA-binding domain at their N-termini.
The abilities of the Rep/SB fusion proteins to recognize
and specifically bind to RRS sequences were examined in a
mammalian one-hybrid reporter assay that measures the
abilities of the SB fusion proteins to reduce the level of
luciferase reporter gene activation via competitive
DNA-binding (Figure 4A).
Cultured HeLa cells were transfected with a luciferase
reporter plasmid having the RRS motif cloned in front of
a minimal promoter (pRRStkLuc) together with limiting
amounts of activator plasmids expressing Rep fused to the
herpes simplex virus VP16 transcriptional activation
domain (RepTZ–AD) and an excess of plasmids express-
ing the corresponding SB fusion transposases. The
unfused SB protein had no RRS-binding activity, and
therefore did not compete with RepTZ–AD, whereas the
addition of excess amounts of RepTZ (lacking AD)
showed significant competition in RRS binding, and
decreased luciferase activation to background levels
(Figure 4B). Upon expression of either Rep/SB, RepLZ/
SB or RepTZ/SB a reduction of 80% in reporter
gene activation level was detected, showing that all
SB transposase fusion proteins were able to compete
with the Rep protein in RRS-binding (Figure 4B).
Apparently, and unexpectedly, the presence of the LZ
and TZ multimerization domains in the RepLZ/SB or
RepTZ/SB fusions did not have a major effect on the
RRS-binding activities of the Rep/transposase fusions.
First, it could be that the transposase partner in the
fusions had a negative effect on the functions of the LZ
and TZ multimerization domains. Second, because Rep
does not bind the RRS as a monomer, it is conceivable
that multimerization of Rep/SB was driven by the SB
transposase that is believed to function as a tetramer
(28), which in turn favoured binding to the RRS. Taken
together, all fusion transposases were competent in trans-
position as well as in binding to the RRS sequence, sug-
gesting that these fusion proteins might prove useful in
redirecting transposon insertions in human cells.
DNA–protein and protein–protein interactions of Rep
fusions with the N57 domain of the SB transposase
Several, naturally occurring transposable elements evolved
strategies to target their insertion into defined sites using
protein–protein interactions between a transposon-
encoded factor and a cellular DNA-binding factor (70).
Adapting such a strategy for targeting transposition
Figure 2. Comparison of integration site selection of the SB, PB and Tol2 transposon systems. The values are presented as the percentage of
integration events divided by the percentage of random events. The horizontal line at value 1 represents the expected random distribution. The
statistical significance of differences from the random control is shown by asterisks above the bars *P 0.05, **P 0.01 and ***P 0.001 (using
Fisher’s exact test). Depicted are the integration frequencies within genes, exons, introns, into 5-kb windows surrounding transcription start sites
(TSS±5-kb) and near sites of the H3K27me3, H3K4me1 and H3K4me3 histone modifications.
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Figure 3. Design, expression and transpositional activities of Rep/SB fusion proteins. (A) Schematic representation of Rep/SB fusion transposases
consisting of the 244 amino acid N-terminal DNA-binding domain of the AAV Rep protein fused to the SB transposase. The RepLZ/SB and
RepTZ/SB fusions contain a GCN4 wild-type (LZ) or modified leucine zipper (TZ) linker domain. (B) Western blot analysis of chimeric transposase
proteins detected with a polyclonal antibody against the SB transposase (anti-SB). The position of a molecular size marker is indicated on the left.
(C) Excision activities of chimeric transposases. HeLa cells were co-transfected with a neomycin-marked (neoR) transposon plasmid together with an
expression plasmid producing either a transposase fusion, unfused transposase as positive control (SB) or the GFP as negative control (control). The
agarose gels show the electrophoretic separation of the 300-bp PCR product diagnostic of transposon excision. The lower gel photograph shows PCR
amplification products of a segment of the neoR-marked transposon plasmids that served as input controls. The positions of the size markers are
indicated on the right. (D) Transpositional activities of chimeric transposases. HeLa cells were co-transfected with a transposon donor plasmid
carrying a selectable neoR gene together with either a transposase-expressing helper plasmid or with a plasmid expressing GFP (control), and cells
were placed under G418 selection. Resistant colonies were fixed, stained and counted. The ratio of colony numbers in the presence versus in the
absence of the transposase is a measure of transposition efficiency. Average relative transpositional activities obtained from three independent
transfections are shown (mean±SD).
Figure 4. DNA-binding activities of transposase fusion proteins. (A) Schematic representation of the competition assay performed to monitor the
RRS-specific DNA-binding activity of transposase fusion proteins in human cells. HeLa cells were transfected with a reporter plasmid containing a
luciferase gene downstream of an RRS site and a minimal thymidine kinase promoter together with limiting amounts of a plasmid expressing the
RepTZ-AD activator protein. Cells also received an excess of plasmids encoding the transposase fusion proteins, the RepTZ protein as positive and
the respective unmodified transposase as negative control. The chimeric transposase proteins and the control proteins were tested for their abilities to
compete in protein binding at the target site, and to thereby reduce the level of luciferase trans-activation in the cell. (B) Luciferase reporter assays
performed with the SB fusion transposases. Each graph displays luciferase activation levels relative to transfection with the respective unmodified
transposase. Bars represent the average (mean±SD) obtained from three independent transfection experiments.
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requires the identification of proteins that interact with the
transposase. Such an interacting protein was previously re-
ported for the SB transposase. The DNA-binding region
of the SB transposase consists of two helix–turn–helix
subdomains (PAI+RED=PAIRED) (Figure 5A). The
N-terminal 57 amino acids (N57) of the transposase en-
compassing the PAI subdomain of the PAIRED complex
mediates specific interactions with the transposase-binding
Figure 5. Design, expression and binding activities of the chimeric N57 fusion proteins. (A) Structure of the SB transposase. The transposase has an
N-terminal paired-like DNA-binding domain consisting of two helix–turn–helix motifs, PAI and RED, and a nuclear localization signal (NLS)
followed by the catalytic domain responsible for the DNA cleavage and joining reactions characterized by the conserved DDE signature. The
targeting fusion proteins consist of the AAV Rep DNA-binding domain (Rep) and the N-terminal interaction domain of the SB transposase (N57).
RepTZ/N57 additionally contained the modified leucine zipper oligomerization domain (TZ). Expression of the N57 fusion proteins was examined by
western blot experiments using a polyclonal antibody against the SB transposase. The position of the molecular size marker is indicated on the left.
(B) One-hybrid assays for monitoring RRS- and IR-binding of N57 fusion proteins. The reporter plasmid for Rep binding contained a luciferase
gene downstream of an RRS motif, whereas the reporter plasmid for IR binding contained a luciferase gene downstream of a 5-mer repeat of the SB
transposase-binding site. Each graph displays luciferase activity relative to transfection with the empty AD vector (pRK5–AD). Bars represent the
average (mean±SD) obtained from three independent transfection experiments. (C) Physical interactions between the SB transposase and the N57
fusion proteins. Interactions between the SB transposase and the Rep/N57 or RepTZ/N57 fusion proteins were examined by co-immunoprecipitation
experiments. The HA-tagged proteins were precipitated with an anti-HA antibody and the immunoprecipitated proteins (IPs) were analysed for the
presence of the Rep/N57 and RepTZ/N57 or the SB transposase proteins by western blot (WB) analysis using a polyclonal anti-SB antibody.
Transfection of Myb-myc served as negative control, for which lysates and IPs were analysed by WB with an anti-myc antibody. The positions of the
molecular size markers are indicated on the right.
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sites within the transposon IRs as well as protein–protein
interactions between transposase subunits (28).
Furthermore, a fusion protein consisting of N57 and the
tetracycline repressor was previously shown to efficiently
target SB integration in 10% of transposant cells into a
chromosomally integrated tetracycline response element in
cultured human cells (71).
We generated fusion transposases consisting of N57 and
Rep with or without TZ, and confirmed their expression
by western blotting (Figure 5A). Active tethering of the
integration complex through N57 fusion proteins requires
RRS-specific-binding activity of the Rep domain as well as
the N57 domain mediating either specific binding to
the transposon IRs or protein–protein interaction with
the SB transposase. The DNA-binding activities of the
N57 fusion proteins were tested in a one-hybrid luciferase
assay using two different reporters. HeLa cells were
co-transfected with the RRS-containing reporter plasmid
pRRStkLuc and an AD-containing expression plasmid.
The expression of RepTZ–AD resulted in significant
(>35-fold) luciferase gene activation as compared to
values obtained with AD domain only (Figure 5B, upper
panel). Upon expression of Rep/N57 and RepTZ/N57, a
7-fold and a 22-fold increase in luciferase gene activation
was observed, respectively (Figure 5B, upper panel).
We included the entire N-terminal DNA-binding domain
including the multimerization domain of the SB
transposase consisting of 123 amino acids fused to AD
(N123-AD) as a further negative control in the experi-
ments. Similar to AD domain only, N123-AD showed
background levels of luciferase transactivation on the
pRRStkLuc reporter (Figure 5B, upper panel), indicating
that the transposase domain does not interact with the
pRRStkLuc plasmid in a non-specific manner. Binding
activities of the N57 fusion proteins to the IRs of the SB
transposon were tested with co-transfection of a reporter
construct having five SB transposase-binding sites cloned
in front of a minimal reporter (pIDRLuc) together with
either of the N57 effector constructs (Figure 5B, lower
panel). The strongest luciferase activation was observed
with N123-AD, consistent with previous studies (Figure
5B, lower panel) (59). Expression of Rep/N57 and RepTZ/
N57 led to an increase in luciferase activation of 1.8-fold
and 6-fold relative to the background level, respectively
(Figure 5B, lower panel). In sum, based on efficient acti-
vation of reporter gene expression, we conclude that both
chimeric proteins were able to bind to the RRS as well as
to the transposon IRs.
Since targeting of the transposition complex could not
only be achieved by binding to the transposon DNA but
also through interaction with the SB transposase protein,
we examined possible physical interactions between N57
fusion proteins and the SB transposase by co-immunopre-
cipitation experiments. This assay was performed in
HeLa cells by co-expressing a haemagglutinin-tagged SB
transposase (HA–SB) together with either of the N57
fusion proteins. The SB transposase and associated
proteins were immunoprecipitated using an anti-HA
antibody, and subsequently subjected to immunoblotting
with a polyclonal anti-SB antibody to examine the
presence of the N57 chimeras. Hybridization of the
anti-SB antibody to the HA-tagged SB as well as to the
Rep/N57 and RepTZ/N57 validated their expression in
co-transfected HeLa cells (Figure 5C, lanes 1 and 2).
Immunoprecipitation with an anti-HA antibody showed
co-precipitation of SB with Rep/N57 (Figure 5C, lane 8),
but not with RepTZ/N57 (Figure 5C, lane 9). These ex-
periments indicated a protein–protein interaction between
the SB transposase and the Rep/N57 fusion protein but
not between SB and RepTZ/N57. The HA–SB and
RepTZ/N57 proteins have similar molecular weights,
and thus were difficult to separate by gel electrophoresis.
We therefore repeated the co-immunoprecipitation assays
with untagged SB transposase and HA-tagged fusion
proteins containing N57 fused to a VP16 AD
(HA–ADRep/N57 and HA–ADRepTZ/N57). As be-
fore, immunoprecipitation experiments revealed co-
precipitation of SB with Rep/N57 (Figure 5C, lane 10),
but not with RepTZ/N57 (Figure 5C, lane 11). To ensure
that the detected interactions were specific, we performed
co-immunoprecipitations with protein lysates from cells
transfected with either SB, Rep/N57 or RepTZ/N57 and
an unrelated Myc-tagged protein of the Harbinger trans-
poson system (Myb-myc) (72). As expected, immunopre-
cipitation with an anti-HA antibody revealed the presence
of proteins interacting with an anti-SB antibody and the
absence of proteins interacting with an anti-myc antibody
(Figure 5C, lanes 12–14).
In sum, the one-hybrid DNA-binding assays showed
that both N57 chimeras retained their abilities to bind
to the RRS motif and to the transposon IRs. The
co-immunoprecipitation assays showed protein–protein
interactions between SB and Rep/N57 but not between
the SB transposase and the RepTZ/N57 fusion protein.
Inter-plasmid targeted transposition
We next tested whether DNA tethering mediated by Rep
could alter transposase target site selection. For this we
made use of a well-established inter-plasmid transposition
assay (54). The assay involves the co-delivery of three dif-
ferent plasmid molecules: (i) a donor plasmid containing a
kanamycin-marked (KanR) transposon, (ii) an ampicillin-
resistant (AmpR) target plasmid with or without RRS
repeats and (iii) a chloramphenicol-resistant helper
plasmid expressing the transposase. All three plasmids
were co-delivered to HeLa cells and allowed to undergo
transposition. The transposase fusions excised the trans-
posons and re-inserted them into the target plasmids re-
sulting in AmpR/KanR double-resistant plasmid
molecules, which were isolated and sequenced to deter-
mine the integration sites in the target plasmids.
Figure 6 summarizes the results of the inter-plasmid
transposition assays performed with the components
of the SB transposon system and the Rep/SB fusion
transposase as well as the chimeric Rep/N57 and
RepTZ/N57 constructs. We mapped 97 Rep/SB-
mediated transposition events into the pFVLuc5xRRS
target plasmid and 91 integrations into the control
plasmid lacking the RRS sites. The target plasmid con-
tained 486 potential TA target sites outside of sequences
that are essential for plasmid maintenance. 81 of these
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sites were used by the Rep/SB transposase. The control
experiment revealed an essentially random integration of
the donor element at multiple TA target sites, whereas in
the presence of the RRS motif Rep/SB-mediated transpos-
ition primarily occurred into one particular TA dinucleo-
tide at plasmid position 3583, 700-bp downstream of the
RRS (Figure 6A). In total, 29 out of 97 mapped insertions
occurred at this TA dinucleotide, representing a 15-fold
increase in integration frequency at this particular site as
compared to the control (P< 0.001 using Student’s t-test).
All of the Rep/SB mediated transposition events into this
specific target site were in a 50–30 orientation with respect
to the RRS motif. The N57 domain of the SB transposase
alone is not able to promote the transposition process. For
this, we added the wild-type SB transposase promoting
excision and insertion of the transposon donor element
to the experimental setup. We mapped 97 insertions that
occurred into the pFVLuc5xRRS target plasmid in the
presence of the Rep/N57 fusion protein, and 98 insertions
were recovered from the control experiment (Figure 6B).
In total, the 195 transposon integrations occurred into 104
TA dinucleotides distributed over the whole plasmid. We
observed some preferred transposon integration sites rep-
resented by multiple insertions into particular TA di-
nucleotides. However, this preference for particular TA
sites in the RRS-containing target plasmid was not differ-
ent from that observed in the control target plasmid
(Figure 6B). The inter-plasmid transposition assay with
RepTZ/N57 fusion protein generated 96 transposition
events in the pFVLuc5xRRS and 102 events in the
control plasmid, with integrations having occurred
into 81 TA sites. The target site distribution in the
RRS-containing target plasmid was almost identical to
that observed in the control plasmid lacking the RRS
motif (Figure 6C).
In conclusion, the results of the plasmid-based integra-
tion assays indicate that the Rep/SB fusion efficiently
targeted transposon insertions into a particular TA site,
whereas preferred integration into particular TA dinucleo-
tides observed in the presence of the Rep/N57 and
Figure 6. Inter-plasmid transposition assay for investigating site-directed transposition. HeLa cells were transfected with a transposase-encoding
plasmid together with a donor plasmid encoding a kanamycin-marked (KanR) transposon and an ampicillin-resistant (AmpR) target plasmid con-
taining five tandem RRS, and allowed to undergo transposition resulting in AmpR/KanR plasmids. Two days post-transfection low-molecular weight
plasmid DNA were isolated and transformed into DH10B E. coli bacteria. AmpR/KanR bacterial colonies were amplified, plasmid DNA isolated and
the locations of transposon insertion sites were determined by DNA sequencing. The schematic maps of the target plasmids show the locations of the
RRS, the AmpR and the ColE1 origin of replication (ColE1ori). The numbers (n) of recovered and mapped integration sites are indicated below the
schemes. The red circles represent insertions of the SB donor element into the pFVLuc5xRRS target plasmid. The blue circles indicate integration
into the pFVLuc control target plasmid lacking the RRS motif. (A) Distribution of Rep/SB-mediated transposon integration sites. (B) Distribution
of SB-mediated transposon integration sites in the presence of the Rep/N57 fusion protein. (C) Distribution of SB-mediated transposon integration
sites in the presence of the RepTZ/N57 fusion protein.
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RepTZ/N57 fusion proteins were presumably independent
from the presence of the targeted RRS sequence in the
plasmid.
Biased insertion profile of SB mediated by Rep in human
cells
Next we addressed the question whether our Rep-based
fusion proteins could target transposon integrations to
genomic sites bound by Rep. We also considered to test
a targeting strategy that employs modifications of the
transposon molecule (Figure 1C). We inserted Rep-
binding sequences into the transposon vector
(Figure 7A), and used these modified transposons
together with an unmodified transposase and the
RRS-binding protein RepTZ to target transposition near
endogenous Rep-binding sequences. We hypothesized that
similar to the process during site-selective integration of
AAV, the RepTZ protein could simultaneously bind to the
RRS sequence in the transposon and to an RRS site in the
genome, thereby guiding the whole transpositional
complex into the vicinity of endogenous RRS sites, at
which the unmodified transposase could then perform
the excision and re-integration of the transposon. On the
basis of the neomycin-marked SB transposon pTneo, we
designed transposon versions with a single RRS motif
(pTneoRRS, Figure 7A) or a 138-bp p5 integration effi-
ciency element (p5IEE) known to enhance Rep-mediated
site-specific integration of AAV (pTneop5IEE, Figure 7A)
(73). We tested this hypothesis not only with the RepTZ
protein, but also with the Rep/N57 and RepTZ/N57
fusion proteins using SB transposons containing add-
itional N57-binding sites in the 30-IR (pTneoDR3,
Figure 7A). All transposon vectors were tested in trans-
position and excision assays and proved to be fully active
(data not shown). There were no differences observed
between transposition efficiencies of the original
(without RRS) and modified (with RRS) transposons,
indicating that the binding of the RepTZ protein did not
interfere with transposition.
We generated large numbers of transposon insertion in
HeLa cells transfected with the different transposon and
transposase components depicted in Figure 7A, recovered
the insertions with LAM–PCR as above, mapped the in-
sertions onto the human genome, and quantified local
features at the integration sites. The integration site data
sets were analysed in relation to integration frequencies
into genes, exons, introns, regions around transcription
start sites (5-kb regions surrounding transcriptional start
sites; 5 kb±TSS), and sites of histone modifications
(Figure 7B). Figure 7B presents the frequency of trans-
poson integrations near the indicated genomic features
divided by the respective frequencies in the computer-
generated random control dataset. As compared to the
wild-type SB transposon system Rep/N57 mediated trans-
position revealed a modest enrichment of integrations into
genes (exon and introns) and into regions surrounding
transcriptional start sites (Figure 7B). Enhanced targeting
of transcriptional start sites was also observed in the
presence of the RepTZ protein (Figure 7B). Notably, all
targeting datasets showed a preference for integrating next
to open chromatin regions characterized by H3K4me1
and H3K4me3 marks, whereas condensed chromatin
regions characterized by H3K27me3 marks were avoided
(Figure 7B).
We next tested whether the Rep-based fusion proteins
could redirect transposon integration into the vicinity of
genomic Rep-binding sites. Since the AAV Rep proteins
bind to combinations of two to four GAGC repeats
(74,75), we adjusted two different potential Rep-binding
site settings: a minimal GAGC GAGC Rep-binding motif
(15 726 sites per human genome) and a consensus GAGC
GAGC GAGC GAGC Rep-binding motif allowing up to
two random mismatches (2134 sites per human genome).
All potential Rep-binding sites in the human genome were
mapped, and the numbers of integrations that occurred in
5-, 10- and 20-kb windows surrounding the binding sites
were determined. The bioinformatic calculations with
GAGC GAGC as a minimal Rep-binding motif revealed
a modest (P 0.05) increase of SB transposon integrations
into a 5-kb interval in the presence of the Rep/SB fusion
transposase (Figure 8A). Our analyses also revealed a stat-
istically significant (P 0.01), 2.7-fold enrichment of SB
transposition events into a 5-kb window around the con-
sensus (GAGC)4 Rep-binding sequence in the presence of
the Rep/N57 targeting protein and the modified
pTneoDR3 transposon (Figure 8B). The significance of
this enrichment disappeared with extended mapping
windows (Figure 8B), indicating that the enrichment
around the RRSs was indeed dependent on physical inter-
action of Rep with the consensus binding sequence.
Notably, the enrichment was only observed with
pTneoDR3 containing an additional N57-binding site
within the right IR of the transposon, and not with the
canonical pTneo transposon (Figure 8B), suggesting a
crucial contribution of N57 binding at the transposon
vector to the observed effect. Given the bias of Rep/SB
and Rep/N57 to mediate insertions nearby TSSs and into
open chromatin regions characterized by H3K4me1 and
H3K4me3 marks (Figure 7B) as well as around RSSs
(Figure 8) a bioinformatics approach was used to investi-
gate the extent of overlap between the distribution of
RSSs and TSSs as well as H3K4me1/3 sites in the
human genome. The analysis revealed that the Rep-
binding sites are indeed quite enriched in TSS and
H3K4me1/3 chromosomal regions (Supplementary
Figure S1). This overlap therefore cross-validates the
data presented in Figures 7 and 8. In conclusion, we
found that the most significant bias towards transposon
insertion around genomic RRS sites required the Rep/N57
protein and an engineered transposon with additional
N57-binding sites, suggesting the role of multiple
protein–DNA interactions in guiding transposon inser-
tions to predetermined sites in the human genome.
Activities of PB and Tol2 transposons
We used the same experimental strategy as above to test
the targeting capabilities of the two other vertebrate trans-
poson systems: PB and Tol2. In accordance with previous
findings suggesting that the PB transposase tolerates
protein additions (76), all Rep/PB fusion transposases
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retained efficient transpositional activities (Supplementary
Figure S2), and efficient RRS-binding activity
(Supplementary Figure S3A). A modified PB transposon
carrying an RRS sequence together with the RepTZ
protein displayed a weak enrichment of transposition
events into relatively large (>10-kb) windows around the
minimal Rep-binding motif (Figure 9A), but none of the
Rep/PB chimeras was able to redirect PB transposon in-
sertion into regions adjacent to genomic consensus
Rep-binding sites (Figure 9B).
The two Rep/Tol2 fusions showed very weak transpos-
itional activities (<10% of the activity of unfused Tol2
transposase (Supplementary Figure S4), but displayed
binding to the RRS motif (Supplementary Figure S3B).
There was no significant enrichment around the minimal
Rep-binding motif seen in any of the datasets (Figure 9C).
However, with the RepL/Tol2 fusion transposase we
observed a 4-fold increase of Tol2 transposon integra-
tions into 5- and 10-kb windows around consensus
Rep-binding motifs (Figure 9D). Thus, these alternative
Figure 7. Comparison of the integration profiles of unfused SB transposase and Rep/SB chimeras. (A) Schematic representation of the transposon
vectors and targeting fusion transposases. (B) Genomic target site distributions. The values are presented as the percentage of integration events
divided by the percentage of random events. Random integration has a value of 1 and is marked by a horizontal line. Depicted are the integration
frequencies within genes, exons, introns, into 5-kb windows surrounding transcription start sites (TSS±5-kb) and near sites of the H3K27me3,
H3K4me1 and H3K4me3 histone modifications. The table below the diagram summarizes the percentage of integrations next to the respective
genomic annotation. The statistical significance of differences from the unfused SB transposase is shown by asterisks above the bars *P 0.05,
**P 0.01 and ***P 0.001.
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transposon systems can also be potentially engineered for
targeted transposition in particular applications.
DISCUSSION
Recent developments in transposon-based technologies
underscore the emerging potential of transposons in
gene therapy applications and induced pluripotent stem
cell generation for regenerative medicine. The SB trans-
poson system demonstrated effective gene delivery and
sustained transgene expression in a variety of vertebrate
organisms including humans. SB combines the integrating
abilities of viral gene therapy vectors needed for stable and
long-lasting transgene expression with the advantageous
properties of easy production, simpler handling and po-
tentially safer chromosomal integration profiles. Studies
on site-directed integration using fusion transposases
may lead to a new approach for inserting exogenous
genes at specific sites and improve the therapeutic appli-
cation of transposon-derived gene therapy vectors. The
integration of a transposon to pre-defined sites in the
genome would ensure appropriate expression of the trans-
gene (lack of position effects) and simultaneously prevent
hazardous effects to the organism due to insertional mu-
tagenesis of cellular genes (lack of genotoxicity).
We performed a large-scale, genome-wide integration
site analysis evaluating the preferences of the SB trans-
poson and two other transposon systems, PB and Tol2,
for their propensities to integrate into genes, transcription
start sites and near histone modifications. The bioinfor-
matic analysis revealed distinct differences between the
three transposon systems (Figure 2). SB had a random
integration profile with no apparent bias for integrating
into genes or near transcriptional regulatory regions of
genes. By contrast, the PB system showed a non-random
integration profile with statistically significant bias
towards integrating into genes, transcription start sites
and their upstream regions. The Tol2 transposon showed
an intermediate integration profile with no bias for insert-
ing into genes, but preferential integration into transcrip-
tion start sites and transcriptional regulatory regions. Tol2
and PB integrations were particularly favoured near tran-
scription start sites and near transcription-associated
histone modifications, including monomethyltated H3K4
(a marker for enhancer regions) and trimethylated H3K4
(associated with promoters of active genes), but disfa-
voured in regions rich in H3K27me3 (a histone modifica-
tion typically associated with transcriptionally repressed
heterochromatin). These data suggest that Tol2 and PB
integration preferences resemble the target site preferences
of retroviral vectors in that HIV- and MLV-derived
vectors strongly favour integration into active genes and
near transcription start sites, respectively (77). These
results are in agreement with a survey of SB, PB and
Tol2 transposon integration sites in primary T cells
showing a random distribution of SB integrations and a
favoured integration of PB and Tol2 near transcriptional
start sites, CpG islands and DNaseI hypersensitive sites
(78). Our analysis suggests that the biased integration site
Figure 8. Mapping of SB transposon integrations in proximity to chromosomal Rep-binding motifs. Transposon insertions were recovered from
HeLa cells transfected with the components of the targeting system. Sequences neighbouring the insertion sites were analysed with respect to
proximity to Rep-binding sites. Calculations were performed with the minimal Rep-binding sequence GAGC GAGC (A) and the consensus
Rep-binding sequence GAGC GAGC GAGC GAGC with up to two mismatches (B). Distances were categorized in 5-, 10- and 20-kb windows
around putative Rep-binding sites and the percentage of insertions obtained in the presence and absence of the targeting fusion proteins in each
category are shown. The percentage of integrations that occurred in the designated windows is represented as bars. The results of statistical tests
comparing the distribution of integration sites generated by the targeting proteins to those generated by unfused SB are summarized as asterisks on
top of each bar. P-values> 0.05 were not considered statistically significant. *P-values< 0.05 were considered significant and **P-values< 0.01 were
considered highly significant.
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distribution of PB and Tol2 transposons might increase
the likelihood for insertional mutagenesis potentially
activating proto-oncogenes or disrupting tumour-
suppressor genes: two effects that need to be avoided in
gene therapeutic approaches. In contrast, SB integration
sites appear to be random compared to Tol2 and PB, and
thus SB likely represents a safer gene transfer vehicle for
application in human gene therapy. However, random in-
tegration of transposon DNA into host chromosomes still
carries a genotoxic risk that needs to be avoided or
minimized for gene-delivery purposes.
In this study we explored the molecular components of
site-selective integration of AAV in order to manipulate
integration site selection of SB, PB and Tol2 in a
proof-of-concept experimental setup (Figure 1). We
evaluated three molecular strategies to target transposon
integrations, all making use of the specific binding of the
AAV Rep protein to a RRS consisting of GAGC repeats.
We incorporated the components of the site-selective
integration machinery of AAV into the transpositional
systems by (i) fusing the N-terminal DNA-binding
domain of Rep to the transposase, (ii) introducing the
RRS-binding site into the transposon DNA and (iii)
fusing the Rep DNA-binding domain to a protein
domain that interacts with the transposon or the
transposase. The rationale behind using only the
DNA-binding domain of Rep was that full-length Rep
proteins are cytotoxic and were shown to induce chromo-
somal rearrangements (18), and that in the context of a
transpositional mechanism only the DNA-binding
function of Rep was required.
We have assessed the feasibility of directly fusing the
DNA-binding domain of the AAV Rep protein to the
transposases, and tested oligomerization motifs known
to promote the multimerization of the Rep proteins,
which is needed for efficient binding to the RRS (60).
We tested the transposon excision and integration
activities of the engineered transposases, and found that
Figure 9. Mapping of PB and Tol2 transposon integrations in proximity to chromosomal Rep-binding motifs. Transposon insertions (A and B, PB;
C and D, Tol2) were recovered from HeLa cells transfected with components of the Rep-based targeting systems. Sequences neighbouring the
insertion sites were analysed with respect to proximity to the next Rep-binding site. Calculations were performed with the following putative
Rep-binding sites: (A and C) minimal Rep-binding site GAGC GAGC and (B and D) consensus Rep-binding site GAGC GAGC GAGC
GAGC with up to two mismatches. Distances were categorized in 5-, 10- and 20-kb windows around putative Rep-binding sites and the percentage
of insertions obtained in the presence and absence of the targeting fusion proteins in each category are shown. The levels of significance are marked
by asterisks. P-values> 0.05 were not considered statistically significant. P-values< 0.05 (*) were considered significant. The PB data set was
composed of 1397 integration sites generated with the unmodified PB transposase (PB+pXLSV40neo), 834 integration sites generated with the
RepTZ/PB chimeric transposase (RepTZ/PB+pXLSV40neo) and 1207 integration sites generated with the RRS-containing PB transposon in the
presence of the Rep DNA-binding protein (RepTZ+pXLSV40neoRRS). The Tol2 integration site analyses comprised 2595 integrations generated
with the unmodified Tol2 transposase (Tol2+pTol2neo), 412 integrations generated with the chimeric RepL/Tol2 transposases and 737 integrations
generated in the presence of the Rep DNA-binding protein and a RRS-containing Tol2 transposon (Rep/TZ+pTol2neoRRS).
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all retained excision and integration capabilities able to
mediate bona fide transposition reactions. Importantly,
both the SB transposase (Figure 3D) as well as the PB
transposase (Supplementary Figure S2D) in fusion with
an N-terminally attached Rep DNA-binding domain
retained up to 80% transpositional activity of that of
the unfused respective transposases. In contrast, fusion
of Rep to the Tol2 transposase severely inhibited trans-
position (Supplementary Figure S4D), suggesting consid-
erable difference in sensitivity of transposases to protein
fusions. We performed a plasmid-based transposition
assay to evaluate the potential of the SB-based fusion
transposases to target pre-defined DNA sites. When
compared to integrations mediated into the control
plasmid, the Rep/SB fusion transposase showed evidence
of directed transposition events into a TA dinucleotide
700-bp downstream of the RRS, representing 30% of all
insertions and a 15-fold enrichment of insertion at that
particular site (Figure 6). In a 2-kb window surrounding
the integration hot spot there were 119 TA sites available
for integration. The pFVLuc plasmid used in this study is
a well-studied target for SB transposition, and was used to
analyse the target-site preferences of the SB transposon
and to develop an automated method that can generate
profiles of predicted integration events (54). According to
this, we deliberately placed the RRS motif into a region
predicted to be disfavoured for SB insertions in the hope
that this would decrease background (non-targeted) inte-
grations within this region. Indeed, the targeted TA di-
nucleotide at position 3583 is a true cold spot for SB
transposition as determined by comparison with the SB
integration distribution in pFVLuc. It is reasonable to
propose that the Rep/SB transposase is structurally con-
strained after binding to the RRS motif, and is therefore
forced to mediate insertion into one particular TA site.
Furthermore, it is conceivable that binding of the Rep
domain to the RRS sequence places the transposon/
transposase complex at some distance from this region,
leading to transposon insertion into a TA dinucleotide
700-bp away. Evidence for this comes from the observa-
tion that all insertions into this particular TA dinucleotide
were at the same orientation with respect to the RRS
motif. Importantly, a bias in insertion site selection was
also seen in our genome-wide analysis: a slight, 1.5-fold
enrichment of integration into 5-kb chromosomal regions
surrounding minimal Rep-binding sites was evident with
Rep/SB. The Rep/PB transposase fusions did not show
evidence of a biased integration profile (Figure 9A,B),
whereas the Rep domain fused to the Tol2 transposase
was apparently quite efficient in resulting a 4-fold en-
richment of insertions near genomic consensus RSS sites
(Figure 9D).
The potential of targeting transposon integration using
fusion proteins with dual DNA-binding activities had
been assessed by engineering RRS sequences into benign
sites within the transposons. The efficiency of targeting
transposition events into endogenous chromosomal RRS
sequences were tested by employing a targeting fusion
protein containing the Rep DNA-binding domain linked
to a tetramerization domain (RepTZ) known to bind effi-
ciently to the RRS motif (60). This approach was
supposed to mimic the natural mechanism of AAV inte-
gration, during which the full-length Rep protein binds to
RRS sequences present in the virus and in the chromo-
some, thereby bringing both components in close vicinity
and mediating viral integration into nearby regions
(Figure 1A). Bridging DNA molecules by proteins was
also proposed to target some P element transposon
vectors in Drosophila. P element vectors containing regu-
latory sequences from the engrailed gene showed some
insertional specificity by frequently integrating near the
endogenous parental gene (79). With this strategy we did
not observe a statistically relevant insertional bias next to
genomic RRS motifs. It is possible that the transposon
molecules bound by the RepTZ proteins accumulate at
the RRS site, whereas the majority of unbound trans-
poson molecules got inserted by the unmodified
transposase at numerous other sites independent from
the RRS sequence.
Several naturally occurring transposable elements have
evolved strategies for targeted insertion into defined
chromosomal sites or regions based on protein–protein
interactions between a transposon-encoded factor and a
cellular DNA-binding factor. One such example is the
bacterial transposon Tn7. The Tn7 element integrates spe-
cifically into the attTn7 site in the E. coli chromosome.
The targeted integration of the element is mediated by a
subunit of the Tn7 transposase named TnsD, which spe-
cifically binds to the attTn7 site, and thereby recruits a
second transposase subunit called TnsC. The TnsC
subunit in turn interacts with the TnsAB transposase,
which then promotes the insertion of Tn7 at attTn7 (80).
Another example is represented by the yeast Ty retro-
transposons. The targeting mechanisms of the Ty1, Ty3
and Ty5 retrotransposons are based on tethering the inte-
gration complexes through interactions with proteins
bound at the respective preferential insertion sites.
Interactions of the retrotransposon-encoded integrase
with components of transcription factor III mediate
targeted integration of Ty1 and Ty3 into regions
upstream of genes transcribed by RNA polymerase III
(81). Targeting of the Ty5 element to heterochromatin is
mediated by the interaction of the retrotransposon-
encoded integrase and the heterochromatin protein Sir4p
(82). The integration of the human immunodeficiency
virus is particularly favoured in active transcription
units. This integration site-selection is controlled by the
cellular transcriptional co-activator lens epithelium-
derived growth factor/p75 (LEDGF/p75), which binds
to the lentiviral integrase and thereby targets integration
into active transcription units (83). Fusions of full-length
LEDGF/p75 or the LEDGF/p75 integrase binding
domain to the DNA-binding domain of phage  repressor
protein showed increased integration near  repressor-
binding sites (84). In a recent study, replacement of the
LEDGF/p75 chromatin interaction-binding domain with
CBX1, a protein binding to di- and trimethylated H3K9
histone molecules associated with pericentric heterochro-
matin and intergenic regions, was shown to direct
lentiviral integration away from genes near regions
bound by the CBX1 protein (85). An approach based on
protein–protein interactions between the SB transposase
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and an engineered targeting protein consisting of the N57
domain and the tetracycline repressor resulted in targeted
integration into a chromosomal TRE region in 10% of
all cells containing transposon insertions (71).
We adapted this strategy by co-expressing the SB
transposase with a targeting fusion protein consisting of
the Rep DNA-binding domain and the N57 subdomain of
the SB transposase, which specifies binding of the
transposase to the IR sequences as well as protein–
protein interactions between transposase molecules. We
designed a direct N57 fusion and one with a separating
tetramerization domain. Co-expression of Rep/N57 or
RepTZ/N57 with the full-length transposase did not
impair transposition. Both fusion proteins showed effi-
cient binding to the RRS sequence, but showed differences
in binding to the transposon/transposase (Figure 5).
RepTZ/N57 was efficiently binding to the transposon
IRs but failed to show protein–protein interaction with
the SB transposase, whereas Rep/N57 showed only
modest binding to the transposon IRs but robust
protein–protein interaction with the SB transposase, sug-
gesting that the multimerization state of N57 fundamen-
tally affects its capacity to engage either in DNA-binding
or protein-binding. The results further indicate that the
intrinsic multimerization domain of the SB transposase
encompassed by the N57 domain is sufficient to mediate
tetramerization of the Rep DNA-binding domain crucial
for efficient binding to the RRS sequence, whereas the
introduction of additional tetramerization domains
interfered with the protein–protein interaction function
of the transposase. Analysis of insertion sites obtained in
the presence of the Rep/N57 fusion protein revealed a
statistically significant enrichment of transposition events
into 5-kb windows surrounding genomic Rep-binding
consensus sequences. This indicates that the Rep/N57
fusion protein was able to direct a relevant number of
transposition complexes to regions adjacent to Rep-
binding sequences occurring with a frequency of only
2134 sites per human genome. A total of 0.184% of all
integrations mediated by the unmodified SB transposase
occurred in this targeting window, whereas in the presence
of Rep/N57 this number raised to 0.494% of all integra-
tions. Notably, this effect was observed with a modified
SB transposon containing an additional N57-binding site
in the 30-IR (pTneoDR3) and not with the unmodified
original transposon (pTneo). These findings suggest that
the additional binding site in the transposon IR had
an enhancing effect on tethering the transpositional
complex, and provide an indication for the composite
effect of protein–protein and protein–DNA interactions.
Furthermore, we observed an increase in transposon inte-
grations into genes and transcription start sites in the
presence of Rep/N57 and RepTZ. This indicates that
Rep/N57 and to some extent also RepTZ had an effect
on the integration site selection of SB, either mediated by
protein–protein or protein–DNA interactions.
We queried the integration site libraries for insertions in
the vicinity of the endogenous AAVS1 locus on chromo-
some 19. Of all integration events analysed we found in
total only three insertion events that could be mapped into
a 20-kb window surrounding the endogenous RRS site in
the AAVS1 locus (data not shown). One insertion was
mediated by the unmodified SB transposase in the
presence of the Rep/N57 fusion, consistent with the
proposed targeting mechanism. However, the two other
integrations were generated by the unmodified SB
transposase alone. Thus, it is clear that the AAVS1 locus
was not targeted in these experiments, and we speculate
that this might be associated with the relative GC-richness
of the AAVS1 locus, which thereby makes this locus rela-
tively unattractive for SB insertions. This prompted us to
investigate the GC-content in 5-kb windows around the
RRS in AAVS1, all other RRSs elsewhere in the genome
and RSSs that were targeted in our datasets. Indeed, GC
content in the AAVS1 site is considerably higher (59%)
than in genomic regions directly flanking other RSSs
(48%) and those RRS sites that were targeted in our ex-
periments (45%) (Supplementary Figure S5), consistent
with the hypothesis that local DNA composition in the
vicinity of a targeted site may have fundamental impact
on the ability of engineered transposases to interact with
that site. Indeed, a recent study showed that ZF/PB
fusions were unable to redirect PB transposons into an
endogenous site in the human genome, and that only en-
gineered, artificial target sequences containing a ZF-
binding site flanked by numerous TTAA sites supported
a modest (2-fold) increase in targeted events (86). In
conclusion, our data suggest that targeted transposition
is likely to be best achieved by a DNA-binding domain
fused to a transposase/transposon-binding protein that
would tether the transposition complex into a desired
locus through protein–protein and additional protein–
DNA interactions. The advantage of such an approach
is that unlike with direct transposase fusions, the tran-
sposase polypeptide does not have to be modified.
Therefore, potential negative effects on transposase
activity are eliminated. Furthermore, this strategy resem-
bles naturally occurring insertion targeting hypothesizing
that the most promising approach for artificially targeting
integration is to mimic nature.
The human genome contains 3.5 billion base pairs,
which complicates efforts for targeted integration. Any
attempt to target specific sites must face an overwhelming
excess of non-specific competitor DNA. All transposases
used in this study were fully functional in target DNA
binding and capture. It is very likely that the intrinsic
target DNA-binding domain of the transposase quickly
binds to random target DNA, and completes the trans-
position reaction rather than dissociating prior to integra-
tion. This non-specific binding of the transposases to
human chromosomal DNA obviously competes with
specific binding to a desired target sequence, thereby
limiting the probabilities of targeted transposition
events. In this context it is important to note that
targeted AAV integration is not as specific for AAVS1
as previously assumed. It was recently found that Rep
targets AAV to integrate into numerous sites in the
human genome showing similarity to RRS (87). Thus, in
light of the presence of numerous sites in the genome com-
petent in Rep binding, the level of enrichment in trans-
poson integration near such sites observed in our study is
promising. Clearly, an important challenge in designing
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sequence-specific transposase fusions will be the reduction
of non-specific DNA-binding. The ultimate goal would be
the design of transposase mutants deficient in target DNA
binding but proficient in catalysis. Moreover, the
DNA-binding domain in a fusion transposase could be
further developed. Approaches exploiting DNA
sequence-specific ZF (88) and TALE (89) DNA-binding
domains to target a genomic sequence of choice represent
promising alternatives.
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